Navigation Links
CoDa Therapeutics Closes $19 Million Series B Financing Round
Date:4/18/2011

SAN DIEGO, April 18, 2011 /PRNewswire/ -- CoDa Therapeutics, Inc. announced today that it has raised $19.2 million in a Series B financing. Current investors Domain Associates, GBS Venture Partners and BioPacificVentures participated in the round. The company expects further Series B financing with participation from additional investors in a second closing, scheduled for a future date.

"The financing will allow us to take essential steps for the development of CoDa; in particular, we will now conduct a large Phase 2 multicenter venous leg ulcer trial in the United States, New Zealand and Australia with Nexagon®, our lead product for chronic wound patients. In addition, we will continue the preclinical development of our product portfolio in our research laboratories," said Bradford Duft, CEO of CoDa.

CoDa is a clinical-stage biopharmaceutical company working to develop a new drug therapy for wounds that do not heal properly, including venous leg and diabetic foot ulcers.  CoDa's lead drug candidate, Nexagon® – a first-in-class compound being tested for its ability to speed healing and reduce inflammation – would be applied topically to stop over-production of a protein known as "connexin43."  CoDa discovered that chronic, poorly healing wounds are characterized by too much continuing connexin43 expression, and that suppression by Nexagon® can improve wound healing.  The company is now working under an FDA-approved IND to generate clinical data in support of eventual regulatory approval for marketing.

CoDa completed a first Phase 2 trial with Nexagon® in 98 patients with venous leg ulcers.  In the drug arm almost one third of patients were completely healed after four weeks following just three application of Nexagon® compared to only 6% complete healing in the placebo arm (p<0.02).

According to Dr. Thomas Serena, a Nexagon® study investigator and Founder and Medical Dire
'/>"/>

SOURCE CoDa Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014 Cyberonics, Inc. (NASDAQ: ... the treatment and management of epilepsy, today announced it will ... Conference on Wednesday, January 14, 2015, in San ... President and Chief Executive Officer, will speak at 11:00 AM ... be accessed by clicking on the Investor Relations link on ...
(Date:12/22/2014)... MARLBOROUGH, Mass , Dec. 22, 2014 /PRNewswire/ -- ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today issued the following open ... Geert Cauwenbergh , Dr. Med. Sc. ... few days a number of inaccurate statements posted ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... campaign launched today highlights the clear choice policymakers in states ... Medicaid program: cut benefits for patients or billions in overpayments ... save $33 billion over the next decade by cutting ... like those in Medicare and commercial plans. ...
... RENO, Nev., June 15, 2011 Visual Healthcare Corp. (the ... announce today that it expects revenues for the fourth quarter ... mid-range of the current guidance is a record high since ... 2011. Based on these figures the Company can provide further ...
Cached Medicine Technology:The Medicaid Choice: Cut Benefits for Patients or Overpayments to Independent Drugstores 2Visual Healthcare Provides Fourth Quarter Revenue Guidance 2
(Date:12/25/2014)... The microscopy market is estimated to ... $5,756.0 million by 2019. Optical microscopy is the ... microscopes product segment is expected to show the ... focus on nanotechnology, technological advancements, and increasing federal ... , Get Full Copy of Report @ ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... of the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ... Liebhard LLP reports. According to an Order issued in ... November 20th, the Court will convene an open conference ... Federal Building and United States Courthouse in West Palm ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... illnesses can receive effective, less expensive care from a clinic ... a team of dedicated health care professionals, a new study ... and need either hospitalization or a trip to the emergency ... clinic at the University of Texas in Houston versus usual ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 AngelWeddingDress.com tries ... to the online realm. Today, the business has introduced ... a site-wide prom dress promotion. , The new prom ... each and every dress lover. They are specially designed ... 2015 prom dresses should visit its website before ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... five cities in one ... ... of the Institute for Integrative Nutrition, the world,s largest,nutrition school, is hosting ... 14. He will demystify the confusion people,experience from all the different dietary ...
... WILMINGTON, Del., May 14 AstraZeneca (NYSE:,AZN) today ... (FDA) has,approved SEROQUEL(R) (quetiapine fumarate tablets) for the ... adjunct therapy to,lithium or divalproex. SEROQUEL is approved ... is also the only single agent approved by ...
... BOULDER, Colo., May 14 Green tea consumption may,promote ... addition,to supporting the medical treatment of some kinds of ... of Alternative Therapies in Health and,Medicine, on newsstands now., ... has anti-cancerous potential,in human stomach and colon cancers, 6 ...
... DUBLIN, May 14 Amarin Corporation plc,(NASDAQ: ... American Depositary,Shares (each representing one ordinary share) ("ADSs") ... certain directors,of the Company, for up to $60 ... new investors, who have entered into definitive agreements ...
... physicians,researchers, Wall Street analysts and industry executives will gather ... 30 - June 1, 2008. With,the most comprehensive and ... this unique venue is focused on,accelerating and sustaining the ... "THE Aesthetic Show offers a weekend immersion in ...
... SYDNEY, Australia, May 14 /PRNewswire-FirstCall/,-- HeartWare Limited (ASX: HTW) ... presentation at the Seventh Annual JMP Securities Research,Conference at ... 21, 2008. The,conference is being held at the Ritz-Carlton, ... the Company,s presentation at the conference will be,available via ...
Cached Medicine News:Health News:Institute for Integrative Nutrition Begins Road Tour 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 2Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 3Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 4Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 5Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 6Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 7Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 8Health News:FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder 9Health News:Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer 2Health News:Amarin Announces Private Placement for up to $60 Million 2Health News:Amarin Announces Private Placement for up to $60 Million 3Health News:Amarin Announces Private Placement for up to $60 Million 4Health News:Amarin Announces Private Placement for up to $60 Million 5Health News:THE Aesthetic Show Advances $34 Billion Market 2Health News:THE Aesthetic Show Advances $34 Billion Market 3Health News:HeartWare to Present at Seventh Annual JMP Securities Research Conference 2
... only control for monitoring total ... fluid samples performed manually using ... an aid for identifying the ... pathological condition present in the ...
... use with Leica Unistat and ... and all automated bilirubin methods ... AU Series, Cobas, Dimension, Hitachi, ... contain purified bilirubin in a ...
... The Dropper Plus is specifically designed for ... room temperature stability eliminates storage problems and ... without refrigeration. A new feature is the ... provided for all analytes; qualitative results for ...
... the ultimate in convenience for urinalysis quality ... DipandSpin is a combination product for dipstick, ... feature is the addition of creatinine and ... as well as for all analytes; qualitative ...
Medicine Products: